This concept is exemplified in the clinical trials where Atezolizumab (anti-PDL1 blockade) was used alone or in combination with Bevacizumab (anti-VEGF therapy) in the treatment of HCC summarized in a recent review by Sangro et al. [15]. This evidence concerns the gene VEGFA and hepatocellular carcinoma.